Skip to main content

Table 1 Cohort demographics

From: Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor

  RA+aTNF RA+MTX RA Healthy Controls
N 61 70 33 97
Age, mean +/- SD years 55.4 +/- 12.3 58.4 +/-12.2 57.1 +/-13.8 39.8 +/- 13.6
% female 82% 77% 64% 63%
Disease duration < 1 year 5% 17% 45% NA
Disease duration > 3 years 93% 60% 47% NA
Adalimumab n (%) 9 (15) NA NA NA
Infliximab n (%) 17 (28) NA NA NA
Etanercept n (%) 35 (57) NA NA NA
MTX n (%) 49 (80) 70 (100) 0 (0) NA
MTX, dose +/- SD mg/wk 15.2 +/- 4.3 16.5 +/- 4.0 NA NA
corticosteroid n (%) 18 (29.5) 26 (37.1) 10 (30.3) NA
corticosteroid, dose +/- SD mg/d 5.5 +/- 3.5 4.9 +/- 2.0 10.3 +/-6.1 NA
ESR mean (range) 21 (4-70) 22 (2-83) 20 (2-74) NA
HAQ mean (range) 0.71 (0.00-2.22) 0.73 (0.00-2.75) 0.46 (0.00-1.63) NA
VAS mean (range) cm 2.8 (0.0-9.8) 3.3 (0.0-7.5) 2.8 (0.0-7.1) NA
Morning stiffness mean (range) min 81 (0-780) 104 (0-1440) 59 (0-180) NA
Race non Caucasian n (%) 8 (13) 6 (9) 2 (6) 12 (12)
  1. ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; NA, not applicable; SD, standard deviation; VAS, visual analogue score.